<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39440811</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1750-2659</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Influenza and other respiratory viruses</Title><ISOAbbreviation>Influenza Other Respir Viruses</ISOAbbreviation></Journal><ArticleTitle>A Strategic Framework of SARS-CoV-2 Genomic Surveillance in Bangladesh.</ArticleTitle><Pagination><StartPage>e70019</StartPage><MedlinePgn>e70019</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e70019</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1111/irv.70019</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The global pandemic caused by SARS-CoV-2 has underlined the significance of strict genomic surveillance to track virus evolution and the possible emergence of new variants, particularly in densely populated countries like Bangladesh. This study outlines a strategic framework of genomic surveillance to track the evolution of the virus in Bangladesh between June 2021 and December 2022 through the National SARS-CoV-2 Variant Surveillance (NSVS) program involving collaboration across 4 major institutes and 13 hospitals nationwide.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We aimed to capture the variants of SARS-CoV-2 throughout the country utilizing standardized procedures, modern sequencing technology, and stringent quality control, promoting data accuracy and the timely detection of new variants of concern. We sequenced over 2200 genomes, documenting the prevalence of the Delta variant initially, followed by the emergence of Omicron variants BA.1, BA.2, BA.5, and XBB, each affecting transmission rates and vaccine efficacy differently.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The clinical manifestations of the variants differed, with some symptoms occurring more frequently in Delta cases and vice versa. Vaccinated individuals were more affected by Omicron cases compared to Delta cases. These variants were responsible for two major COVID-19 waves in the country, each with significant clinical effects. Phylogenetic analyses placed the local SARS-CoV-2 variants within a global context, indicating the Delta variant likely entered from India and Omicron from Europe.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This research highlights the significance of collaborative surveillance strategies for guiding public health choices and the critical role of genomic analysis in monitoring virus evolution, shaping targeted pandemic responses. Bangladesh's contributions significantly enhance global insight into COVID-19's genomic evolution.</AbstractText><CopyrightInformation>© 2024 The Author(s). Influenza and Other Respiratory Viruses Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jubair</LastName><ForeName>Mohammad</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0249-0974</Identifier><AffiliationInfo><Affiliation>Genome Centre, Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hossain</LastName><ForeName>Md Mobarok</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Genome Centre, Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Begum</LastName><ForeName>Mst Noorjahan</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moon</LastName><ForeName>Shovan Basak</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Genome Centre, Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Islam</LastName><ForeName>Shahriar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Genome Centre, Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karim</LastName><ForeName>Md Yeasir</ForeName><Initials>MY</Initials><AffiliationInfo><Affiliation>Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rahman</LastName><ForeName>Sezanur</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-0092-9261</Identifier><AffiliationInfo><Affiliation>Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Manjur H</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Department of Virology, Institute of Epidemiology, Disease Control and Research, Dhaka, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Habib</LastName><ForeName>Mohammad Tanbir</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Institute for Developing Science and Health Initiatives (ideSHi), Dhaka, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shirin</LastName><ForeName>Tahmina</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Virology, Institute of Epidemiology, Disease Control and Research, Dhaka, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qadri</LastName><ForeName>Firdausi</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Developing Science and Health Initiatives (ideSHi), Dhaka, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rahman</LastName><ForeName>Mustafizur</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Genome Centre, Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>GR 32070</GrantID><Agency>Bill and Melinda Gates Foundation</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Influenza Other Respir Viruses</MedlineTA><NlmUniqueID>101304007</NlmUniqueID><ISSNLinking>1750-2640</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001459" MajorTopicYN="N" Type="Geographic">Bangladesh</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016679" MajorTopicYN="Y">Genome, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D023281" MajorTopicYN="N">Genomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010802" MajorTopicYN="N">Phylogeny</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bangladesh</Keyword><Keyword MajorTopicYN="N">COVID‐19</Keyword><Keyword MajorTopicYN="N">Delta</Keyword><Keyword MajorTopicYN="N">Omicron</Keyword><Keyword MajorTopicYN="N">SARS‐CoV‐2</Keyword><Keyword MajorTopicYN="N">surveillance</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>16</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>7</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39440811</ArticleId><ArticleId IdType="pmc">PMC11497173</ArticleId><ArticleId IdType="doi">10.1111/irv.70019</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Campbell F., Archer B., Laurenson‐Schafer H., et al., “Increased Transmissibility and Global Spread of SARS‐CoV‐2 Variants of Concern as at June 2021,” Euro Surveillance 26, no. 24 (2021): 2100509, 10.2807/1560-7917.ES.2021.26.24.2100509.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2021.26.24.2100509</ArticleId><ArticleId IdType="pmc">PMC8212592</ArticleId><ArticleId IdType="pubmed">34142653</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodcroft E. B., Zuber M., Nadeau S., et al., “Spread of a SARS‐CoV‐2 Variant Through Europe in the Summer of 2020,” Nature 595, no. 7869 (2021): 707–712, 10.1038/s41586-021-03677-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03677-y</ArticleId><ArticleId IdType="pubmed">34098568</ArticleId></ArticleIdList></Reference><Reference><Citation>Bugembe D. L., Phan M. V. T., Ssewanyana I., et al., “Emergence and Spread of a SARS‐CoV‐2 Lineage a Variant (A.23.1) With Altered Spike Protein in Uganda,” Nature Microbiology 6 (2021): 1094–1101, 10.1038/s41564-021-00933-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-021-00933-9</ArticleId><ArticleId IdType="pmc">PMC8318884</ArticleId><ArticleId IdType="pubmed">34163035</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson E., Giovanetti M., Tegally H., et al., “A Year of Genomic Surveillance Reveals How the SARS‐CoV‐2 Pandemic Unfolded in Africa,” Science 374, no. 6566 (2021): 423–431, 10.1126/science.abj4336.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abj4336</ArticleId><ArticleId IdType="pmc">PMC7613315</ArticleId><ArticleId IdType="pubmed">34672751</ArticleId></ArticleIdList></Reference><Reference><Citation>López M. G., Chiner‐Oms Á., García de Viedma D., et al., “The First Wave of the COVID‐19 Epidemic in Spain Was Associated With Early Introductions and Fast Spread of a Dominating Genetic Variant,” Nature Genetics 53, no. 10 (2021): 1405–1414, 10.1038/s41588-021-00936-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-021-00936-6</ArticleId><ArticleId IdType="pmc">PMC8481935</ArticleId><ArticleId IdType="pubmed">34594042</ArticleId></ArticleIdList></Reference><Reference><Citation>Jahan M., Bhattacharjee A., Rahmat R., et al., “Genomic Surveillance of SARS‐CoV‐2 Viruses Collected During the Ending Phase of the First Wave of the COVID‐19 Pandemic in Bangladesh,” Microbiology Resource Announcements 10, no. 29 (2021): e0049621, 10.1128/MRA.00496-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MRA.00496-21</ArticleId><ArticleId IdType="pmc">PMC8297457</ArticleId><ArticleId IdType="pubmed">34292071</ArticleId></ArticleIdList></Reference><Reference><Citation>Haque R., Hossain M. E., Miah M., et al., “Monitoring SARS‐CoV‐2 Variants in Wastewater of Dhaka City, Bangladesh: Approach to Complement Public Health Surveillance Systems,” Human Genomics 17 (2023): 58, 10.1186/s40246-023-00505-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40246-023-00505-4</ArticleId><ArticleId IdType="pmc">PMC10326934</ArticleId><ArticleId IdType="pubmed">37420264</ArticleId></ArticleIdList></Reference><Reference><Citation>Bari R. and Sultana F., “Second Wave of COVID‐19 in Bangladesh: An Integrated and Coordinated Set of Actions Is Crucial to Tackle Current Upsurge of Cases and Deaths,” Frontiers in Public Health 9 (2021): 699918, 10.3389/fpubh.2021.699918.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2021.699918</ArticleId><ArticleId IdType="pmc">PMC8437241</ArticleId><ArticleId IdType="pubmed">34527649</ArticleId></ArticleIdList></Reference><Reference><Citation>Tegally H., San J. E., Cotten M., et al., “The Evolving SARS‐CoV‐2 Epidemic in Africa: Insights From Rapidly Expanding Genomic Surveillance,” Science 378 (2022): eabq5358, 10.1126/science.abq5358.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abq5358</ArticleId><ArticleId IdType="pmc">PMC9529057</ArticleId><ArticleId IdType="pubmed">36108049</ArticleId></ArticleIdList></Reference><Reference><Citation>Bugembe D. L., Kayiwa J., Phan M. V. T., et al., “Main Routes of Entry and Genomic Diversity of SARS‐CoV‐2, Uganda,” Emerging Infectious Diseases 26, no. 10 (2020): 2411–2415, 10.3201/eid2610.202575.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2610.202575</ArticleId><ArticleId IdType="pmc">PMC7510740</ArticleId><ArticleId IdType="pubmed">32614767</ArticleId></ArticleIdList></Reference><Reference><Citation>Mashe T., Takawira F. T., de Oliveira Martins L., et al., “Genomic Epidemiology and the Role of International and Regional Travel in the SARS‐CoV‐2 Epidemic in Zimbabwe: A Retrospective Study of Routinely Collected Surveillance Data,” The Lancet Global Health 9 (2021): e1658–e1666, 10.1016/S2214-109X(21)00434-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(21)00434-4</ArticleId><ArticleId IdType="pmc">PMC8536247</ArticleId><ArticleId IdType="pubmed">34695371</ArticleId></ArticleIdList></Reference><Reference><Citation>Chouikha A., Fares W., Laamari A., et al., “Molecular Epidemiology of SARS‐CoV‐2 in Tunisia (North Africa) Through Several Successive Waves of COVID‐19,” Viruses 14, no. 2 (2022): 624, 10.3390/v14020624.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14020624</ArticleId><ArticleId IdType="pmc">PMC8956073</ArticleId><ArticleId IdType="pubmed">35337031</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y., Wu Q., Song P., and You C., “The Variation of SARS‐CoV‐2 and Advanced Research on Current Vaccines,” Frontiers in Medicine 8 (2022): 806641, 10.3389/fmed.2021.806641.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.806641</ArticleId><ArticleId IdType="pmc">PMC8804231</ArticleId><ArticleId IdType="pubmed">35118097</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoteit R. and Yassine H. M., “Biological Properties of SARS‐CoV‐2 Variants: Epidemiological Impact and Clinical Consequences,” Vaccine 10, no. 6 (2022): 919, 10.3390/vaccines10060919.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10060919</ArticleId><ArticleId IdType="pmc">PMC9230982</ArticleId><ArticleId IdType="pubmed">35746526</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohapatra R. K., Mahal A., Kutikuppala L. V. S., et al., “Renewed Global Threat by the Novel SARS‐CoV‐2 Variants ‘XBB, BF.7, BQ.1, BA.2.75, BA.4.6’: A Discussion,” Frontiers in Virology 2 (2022): 1077155, 10.3389/fviro.2022.1077155.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fviro.2022.1077155</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung H. Y., Jian M. J., Chang C. K., et al., “Emergency SARS‐CoV‐2 Variants of Concern: Novel Multiplex Real‐Time RT‐PCR Assay for Rapid Detection and Surveillance,” Microbiology Spectrum 10, no. 1 (2022): e0251321, 10.1128/spectrum.02513-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/spectrum.02513-21</ArticleId><ArticleId IdType="pmc">PMC8865422</ArticleId><ArticleId IdType="pubmed">35196812</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith M. F., Holland S. C., Lee M. B., et al., “Baseline Sequencing Surveillance of Public Clinical Testing, Hospitals, and Community Wastewater Reveals Rapid Emergence of SARS‐CoV‐2 Omicron Variant of Concern in Arizona, USA,” MBio 14, no. 1 (2023): e0310122, 10.1128/mbio.03101-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mbio.03101-22</ArticleId><ArticleId IdType="pmc">PMC9972916</ArticleId><ArticleId IdType="pubmed">36622143</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown C. M., Vostok J., Johnson H., et al., “Outbreak of SARS‐CoV‐2 Infections, Including COVID‐19 Vaccine Breakthrough Infections, Associated With Large Public Gatherings—Barnstable County, Massachusetts, July 2021,” MMWR. Morbidity and Mortality Weekly Report 70 (2021): 1059–1062, 10.15585/mmwr.mm7031e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7031e2</ArticleId><ArticleId IdType="pmc">PMC8367314</ArticleId><ArticleId IdType="pubmed">34351882</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheikh A., McMenamin J., Taylor B., Robertson C., and Public Health Scotland and the EAVE II Collaborators , “SARS‐CoV‐2 Delta VOC in Scotland: Demographics, Risk of Hospital Admission, and Vaccine Effectiveness,” The Lancet 397 (2021): 2461–2462, 10.1016/S0140-6736(21)01358-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01358-1</ArticleId><ArticleId IdType="pmc">PMC8201647</ArticleId><ArticleId IdType="pubmed">34139198</ArticleId></ArticleIdList></Reference><Reference><Citation>
Directorate General of Health Services (DGHS)
. “Coronavirus (COVID‐19) Update”. Retrieved from https://dghs.gov.bd/index.php/en/home/5343‐covid‐19‐update (2021).</Citation></Reference><Reference><Citation>Rahman M., Shirin T., Rahman S., et al., “The Emergence of SARS‐CoV‐2 Variants in Dhaka City, Bangladesh,” Transboundary and Emerging Diseases 68, no. 6 (2021): 3000–3001, 10.1111/tbed.14203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tbed.14203</ArticleId><ArticleId IdType="pmc">PMC8447378</ArticleId><ArticleId IdType="pubmed">34170629</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasan M. M., Rocha I. C. N., Ramos K. G., et al., “Emergence of Highly Infectious SARS‐CoV‐2 Variants in Bangladesh: The Need for Systematic Genetic Surveillance as a Public Health Strategy,” Tropical Medicine and Health 49, no. 1 (2021): 69, 10.1186/s41182-021-00360-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41182-021-00360-w</ArticleId><ArticleId IdType="pmc">PMC8408563</ArticleId><ArticleId IdType="pubmed">34470674</ArticleId></ArticleIdList></Reference><Reference><Citation>Twohig K. A., Nyberg T., Zaidi A., et al., “Hospital Admission and Emergency Care Attendance Risk for SARS‐CoV‐2 Delta (B.1.617.2) Compared With Alpha (B.1.1.7) Variants of Concern: A Cohort Study,” The Lancet Infectious Diseases 22, no. 1 (2022): 35–42, 10.1016/S1473-3099(21)00475-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00475-8</ArticleId><ArticleId IdType="pmc">PMC8397301</ArticleId><ArticleId IdType="pubmed">34461056</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D., Veyer D., Baidaliuk A., et al., “Reduced Sensitivity of SARS‐CoV‐2 Variant Delta to Antibody Neutralization,” Nature 596 (2021): 276–280, 10.1038/s41586-021-03777-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03777-9</ArticleId><ArticleId IdType="pubmed">34237773</ArticleId></ArticleIdList></Reference><Reference><Citation>Richi F. T., Alam S., Ahmed F., and Al‐Hossain A. S. M. M., “The Outbreak of Delta Plus Variant: The Notorious and Novel Strain of SARS‐CoV‐2,” Clinical Epidemiology and Global Health 14 (2022): 100974, 10.1016/j.cegh.2022.100974.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cegh.2022.100974</ArticleId><ArticleId IdType="pmc">PMC8817758</ArticleId><ArticleId IdType="pubmed">35155845</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockett R., Basile K., Maddocks S., et al., “Resistance Mutations in SARS‐CoV‐2 Delta Variant After Sotrovimab Use,” The New England Journal of Medicine 386 (2022): 1477–1479, 10.1056/NEJMc2120219.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2120219</ArticleId><ArticleId IdType="pmc">PMC8929376</ArticleId><ArticleId IdType="pubmed">35263515</ArticleId></ArticleIdList></Reference><Reference><Citation>Islam M. R., “The SARS‐CoV‐2 Omicron (B.1.1.529) Variant and the re‐Emergence of COVID‐19 in Europe: An Alarm for Bangladesh. Health,” Science Reports 5 (2022): e545, 10.1002/hsr2.545.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hsr2.545</ArticleId><ArticleId IdType="pmc">PMC8918917</ArticleId><ArticleId IdType="pubmed">35308422</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D., Saunders N., Maes P., et al., “Considerable Escape of SARS‐CoV‐2 Omicron to Antibody Neutralization,” Nature 602 (2022): 671–675.</Citation><ArticleIdList><ArticleId IdType="pubmed">35016199</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R. E., Zhang X., Case J. B., et al., “Resistance of SARS‐CoV‐2 Variants to Neutralization by Monoclonal and Serum‐Derived Polyclonal Antibodies,” Nature Medicine 27, no. 4 (2021): 717–726, 10.1038/s41591-021-01294-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01294-w</ArticleId><ArticleId IdType="pmc">PMC8058618</ArticleId><ArticleId IdType="pubmed">33664494</ArticleId></ArticleIdList></Reference><Reference><Citation>Saville J. W., Mannar D., Zhu X., et al., “Structural and Biochemical Rationale for Enhanced Spike Protein Fitness in Delta and Kappa SARS‐CoV‐2 Variants,” Nature Communications 13, no. 1 (2022): 742, 10.1038/s41467-022-28324-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-28324-6</ArticleId><ArticleId IdType="pmc">PMC8826856</ArticleId><ArticleId IdType="pubmed">35136050</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y., Yisimayi A., Jian F., et al., “BA.2.12.1, BA.4 and BA.5 Escape Antibodies Elicited by Omicron Infection,” Nature 608 (2022): 593–602.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9385493</ArticleId><ArticleId IdType="pubmed">35714668</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Guo Y., Iketani S., et al., “Antibody Evasion by SARS‐CoV‐2 Omicron Subvariants BA.2.12.1, BA.4 and BA.5,” Nature 608 (2022): 603–608 PMID: 35790190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9385487</ArticleId><ArticleId IdType="pubmed">35790190</ArticleId></ArticleIdList></Reference><Reference><Citation>Carabelli A. M., Peacock T. P., Thorne L. G., et al., “SARS‐CoV‐2 Variant Biology: Immune Escape, Transmission and Fitness,” Nature Reviews. Microbiology 21 (2023): 162–177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9847462</ArticleId><ArticleId IdType="pubmed">36653446</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller J., Hachmann N. P., Collier A.‐R. Y., et al., “Substantial Neutralization Escape by SARS‐CoV‐2 Omicron Variants BQ.1.1 and XBB.1,” The New England Journal of Medicine 388 (2023): 662–664.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9878581</ArticleId><ArticleId IdType="pubmed">36652339</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D., Bruel T., Staropoli I., et al., “Resistance of Omicron Subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to Neutralizing Antibodies,” Nature Communications 14 (2023): 824.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9926440</ArticleId><ArticleId IdType="pubmed">36788246</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu P., Evans J. P., Faraone J. N., et al., “Enhanced Neutralization Resistance of SARS‐CoV‐2 Omicron Subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2,” Cell Host &amp; Microbe 31 (2023): 9–17.e3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9678813</ArticleId><ArticleId IdType="pubmed">36476380</ArticleId></ArticleIdList></Reference><Reference><Citation>Jubair M., Begum M. N., Rahman S., et al., “SARS‐CoV‐2 Omicron Variants in Bangladesh: Pandemic to Endemic,” Health Science Reports 6, no. 3 (2023): e1134, 10.1002/hsr2.1134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hsr2.1134</ArticleId><ArticleId IdType="pmc">PMC9981876</ArticleId><ArticleId IdType="pubmed">36875934</ArticleId></ArticleIdList></Reference><Reference><Citation>Tosta S., Moreno K., Schuab G., et al., “Global SARS‐CoV‐2 Genomic Surveillance: What We Have Learned (So Far),” Infection, Genetics and Evolution 108 (2023): 105405, 10.1016/j.meegid.2023.105405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.meegid.2023.105405</ArticleId><ArticleId IdType="pmc">PMC9847326</ArticleId><ArticleId IdType="pubmed">36681102</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcantara L. C. J., Nogueira E., Shuab G., et al., “SARS‐CoV‐2 Epidemic in Brazil: How the Displacement of Variants Has Driven Distinct Epidemic Waves,” Virus Research 315 (2022): 198785, 10.1016/j.virusres.2022.198785.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2022.198785</ArticleId><ArticleId IdType="pmc">PMC9022374</ArticleId><ArticleId IdType="pubmed">35461905</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedford J., Enria D., Giesecke J., et al., “COVID‐19: Towards Controlling a Pandemic,” The Lancet 395, no. 10229 (2020): 1015–1018, 10.1016/S0140-6736(20)30673-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30673-5</ArticleId><ArticleId IdType="pmc">PMC7270596</ArticleId><ArticleId IdType="pubmed">32197103</ArticleId></ArticleIdList></Reference><Reference><Citation>Boehm E., Kronig I., Neher R. A., Eckerle I., Vetter P., and Kaiser L., “Novel SARS‐CoV‐2 Variants: The Pandemics Within the Pandemic,” Clinical Microbiology and Infection 27, no. 8 (2021): 1109–1117, 10.1016/j.cmi.2021.05.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.05.022</ArticleId><ArticleId IdType="pmc">PMC8127517</ArticleId><ArticleId IdType="pubmed">34015535</ArticleId></ArticleIdList></Reference><Reference><Citation>Brito A. F., Semenova E., Dudas G., et al., “Global Disparities in SARS‐CoV‐2 Genomic Surveillance,” Nature Communications 13 (2022): 7003, 10.1038/s41467-022-33713-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-33713-y</ArticleId><ArticleId IdType="pmc">PMC9667854</ArticleId><ArticleId IdType="pubmed">36385137</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C., Shi Y., Zhang P., and Ding C., “A Cross‐Country Comparison of Fiscal Policy Responses to the COVID‐19 Global Pandemic,” Journal of Comparative Policy Analysis: Research and Practice 23, no. 2 (2021): 262–273, 10.1080/13876988.2021.1878885.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13876988.2021.1878885</ArticleId></ArticleIdList></Reference><Reference><Citation>Haug N., Geyrhofer L., Londei A., et al., “Ranking the Effectiveness of Worldwide COVID‐19 Government Interventions,” Nature Human Behaviour 4, no. 12 (2020): 1303–1312, 10.1038/s41562-020-01009-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41562-020-01009-0</ArticleId><ArticleId IdType="pubmed">33199859</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoang T., da Silva A. G., Jennison A. V., Williamson D. A., Howden B. P., and Seemann T., “AusTrakka: Fast‐Tracking Nationalized Genomics Surveillance in Response to the COVID‐19 Pandemic,” Nature Communications 13, no. 1 (2022): 865, 10.1038/s41467-022-28529-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-28529-9</ArticleId><ArticleId IdType="pmc">PMC8844306</ArticleId><ArticleId IdType="pubmed">35165271</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>